美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Militia Long/Short Equity ETF

35.81

-0.4800-1.32%

盘后：35.810.00000.00%19:57 EDT

成交量：40.04万

成交额：1,439.49万

市值：4.25亿

市盈率：- -

高：36.29

开：36.16

低：35.72

收：36.29

52周最高：39.39

52周最低：25.85

股本：1,188.00万

流通股本：1,188.00万

量比：2.13

换手率：3.37%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

EGFR 20ins二线治疗战场硝烟再起舒沃替尼全线布局伏美替尼能否破局？| 新药价值解码

Pan-KRAS赛道的新变量：JAB-23E73的胰腺癌ORR 38.5%背后的估值差

加科思药业公布2025年度业绩

达唯珂折戟，创新药研发安全红线再敲警钟

21世纪经济报道

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ORR"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":35.81,"timestamp":1774641600000,"preClose":36.29,"halted":0,"volume":400387,"hourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01322678423808203,"floatShares":11880000,"shares":11880000,"eps":0,"marketStatus":"休市中","change":-0.48,"latestTime":"03-27 16:00:00 EDT","open":36.16,"high":36.29,"low":35.72,"amount":14394852.358289002,"amplitude":0.015707,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":36.29,"sharesOutstanding":12900000,"nav":36.65,"aum":435402000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":36.18,"preClose":36.29,"latestTime":"09:19 EDT","volume":11,"amount":397.98,"timestamp":1774617580197,"change":-0.11,"changeRate":-0.003031,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.1271713616895913,"impliedVol":0.0274,"impliedVolPercentile":0.0357},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":11880000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.1271713616895913,"shares":11880000,"dividePrice":0,"high":36.29,"amplitude":0.015707,"preClose":36.29,"low":35.72,"week52Low":25.85,"pbRate":"--","week52High":39.39,"institutionHeld":0,"latestPrice":35.81,"eps":0,"divideRate":0,"volume":400387,"delay":0,"ttmEps":0,"open":36.16,"prevYearClose":34.16,"prevWeekClose":35.79,"prevMonthClose":39.08,"prevQuarterClose":34.16,"fiveDayClose":35.79,"twentyDayClose":39.08,"sixtyDayClose":34.345},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622846838","title":"EGFR 20ins二线治疗战场硝烟再起 舒沃替尼全线布局伏美替尼能否破局？| 新药价值解码","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846838","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622846838?lang=zh_cn&edition=fundamental","pubTime":"2026-03-27 15:58","pubTimestamp":1774598280,"startTime":"0","endTime":"0","summary":"　　CSCO指南的推荐级别，是连接高级别医学证据与复杂临床决策的桥梁。近日，艾力斯公告显示，公司提交的甲磺酸伏美替尼片EGFR 20号外显子插入突变NSCLC二线治疗适应症药品注册申请的办理环节已更新为“审批完毕-待制证”。与携带常见EGFR突变的患者相比，携带EGFR外显子20插入突变的患者通常预后较差。艾力斯的伏美替尼聚焦的同样为EGFR 20号外显子插入突变非小细胞肺癌二线治疗，将与舒沃替尼形成直接竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-03-27/doc-inhsmhtu5367500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4097","ORR","OS"],"gpt_icon":0},{"id":"2618995755","title":"Pan-KRAS赛道的新变量：JAB-23E73的胰腺癌ORR 38.5%背后的估值差","url":"https://stock-news.laohu8.com/highlight/detail?id=2618995755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618995755?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 09:20","pubTimestamp":1773192006,"startTime":"0","endTime":"0","summary":"Pan-KRAS赛道最近披露了一组很值得细看的数据。加科思公布了JAB-23E73在胰腺癌患者中的一期研究结果。目前披露的JAB-23E73安全性数据来自42例患者。RMC-6236的血液及肝肾毒性三级治疗相关不良事件为4%-7%，综合来看JAB-23E73安全性更优。JAB-23E73在160mg以上治疗组中，在可评估的13例KRAS突变胰腺癌患者中，有2例是二线治疗，剩下11例都是三线或三线以上的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ORR","BK1161","BK1574","01167"],"gpt_icon":0},{"id":"2618495271","title":"加科思药业公布2025年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618495271","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618495271?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 23:30","pubTimestamp":1773156600,"startTime":"0","endTime":"0","summary":"首个商业化产品戈来雷塞片在中国获批并纳入医保 pan-KRAS及创新ADC管线持续推进 北京、上海和波士顿2026年3月10日 /美通社/ -- 加科思药业集团有限公司今日公布截至2025年12月31日止年度业绩，并更新公司核心研发管线进展。自2025年6月至12月，加科思确认收入855万元。截至2026年1月15日，中国一期试验共入组42例患者。该项目预计于2026年下半年提交IND申请。公司预计2026年第一季度该余额将超过20亿元，并预计2026年实现扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4906510_ZH06510_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ORR","BK1574","BK1161","01167"],"gpt_icon":0},{"id":"2618987798","title":"达唯珂折戟，创新药研发安全红线再敲警钟","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987798","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618987798?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 09:14","pubTimestamp":1773105251,"startTime":"0","endTime":"0","summary":"达唯珂由法国药企益普生旗下Epizyme开发，为全球同类首创的EZH2甲基转移酶抑制剂。达唯珂是全球首个且唯一获批用于滤泡性淋巴瘤的口服EZH2抑制剂。此次产品撤市、相关临床试验全面终止后，该细分领域精准治疗方案的空白将再次凸显，临床未满足需求亟待新一代创新药填补。2025年4月，公司以6.085亿美元现金出售上海和黄药业45%股权，仅保留5%股权，全面聚焦创新药研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ18W456.USD","IE0009354923.USD","LU2449327464.USD","IE00BMG7P694.USD","IE00B66KJ199.SGD","LU1880398554.USD","LU1880398471.USD","IE0031619046.USD","IE00BMG7P926.USD","IE00BZ18W340.USD","LU1803068623.USD","HCM","LU0390134368.USD","IE00B29SXK94.USD","IE00B29SXL02.USD","IE00B19Z4B17.USD","BK4588","LU1228905037.USD","ORR","BK4006","BK4226","LU2065731478.USD","LU1228905540.USD","IE0034235188.USD","BK4081","BK4106","LU0545562505.USD","PFS","IE00BMG7P819.SGD","BK4211","BK4531","BK4187","IE00BMQBXF63.USD","CRS","LU1883839398.USD","BR","BK4548","LU0963586101.USD","LU2637428348.USD","IE00B7SZL793.SGD","BK4007","IE00BMG7P587.USD","ES","BK4585","BK4195"],"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}